Our company has collaborated with Okayama University to establish the research framework for a Phase I clinical trial of the B-NIT therapy and has signed an outsourced development contract. We are preparing for physician-led clinical trials, and it is expected to have minimal impact on our performance in fiscal year 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4888","jir_company_name":"Stella Farm Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4888-20260727-01.pdf","jir_short_summary":"Our company has collaborated with Okayama University to establish the research framework for a Phase I clinical trial of the B-NIT therapy and has signed an outsourced development contract. We are preparing for physician-led clinical trials, and it is expected to have minimal impact on our performance in fiscal year 2027.","jir_summary":"### Overview of Research and Development\nOur company has jointly with Okayama University established the research framework for creating a protocol for a Phase I clinical trial using B-NIT (Boron Neutron Immunotherapy) and has signed an outsourced research and development agreement. B-NIT is a new treatment concept combining BNCT and immunotherapy, targeting patients with advanced melanoma. The study is scheduled from April 2026 to March 2027, aiming to initiate physician-led clinical trials in the future.\n\n### Future Outlook and Impact\nProgress of this research is expected to have a minimal impact on our performance for the fiscal year ending March 2027. We will promptly disclose any new developments or important matters and will proceed with efforts towards clinical trial initiation and practical application of the therapy as progress is made.","jir_financial_highlights":"Research and Development Period: From April 1, 2026 to March 31, 2027 (Unknown)","jir_category":"","jir_hashtags":"#StellaPharmaceutical, #IRrelated, #JapanStocks","jir_key_figures":"Research Period: April 1, 2026 to March 31, 2027\nContract Partner: Outsourced research and development agreement with Okayama University\nTarget Disease: Unresectable BRAF-negative advanced melanoma","jir_meta_title":"\u3010Stella Pharmaceutical\u3011Confirmed Research Framework for New Treatment\uff5cJuly 2026","jir_meta_description":"Stella Pharmaceutical is collaborating with Okayama University and is advancing preparations for the clinical trial of B-NIT therapy. The impact on FY2027 performance is expected to be minimal.","jir_og_title":"\u3010Stella Pharmaceutical\u3011Confirmed Research Framework for New Treatment\uff5cJuly 2026","jir_og_description":"Stella Pharmaceutical is collaborating with Okayama University and is advancing preparations for the clinical trial of B-NIT therapy. The impact on FY2027 performance is expected to be minimal.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59263,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-88480","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n